Response To Comments Article

Response to Comments: Glucose Monitors – DL33822

A58798

Expand All | Collapse All

Contractor Information

Contractor Name	Contract Type	Contract Number	Jurisdiction	States
CGS Administrators, LLC	DME MAC	17013 - DME MAC	J-B	Illinois Indiana Kentucky Michigan Minnesota Ohio Wisconsin
CGS Administrators, LLC	DME MAC	18003 - DME MAC	J-C	Alabama Arkansas Colorado Florida Georgia Louisiana Mississippi New Mexico North Carolina Oklahoma Puerto Rico South Carolina Tennessee Texas Virgin Islands Virginia West Virginia
Noridian Healthcare Solutions, LLC	DME MAC	16013 - DME MAC	J-A	Connecticut Delaware District of Columbia Maine Maryland Massachusetts New Hampshire New Jersey New York - Entire State Pennsylvania Rhode Island Vermont
Noridian Healthcare Solutions, LLC	DME MAC	19003 - DME MAC	J-D	Alaska American Samoa Arizona California - Entire State Guam Hawaii Idaho Iowa Kansas Missouri - Entire State Montana Nebraska Nevada North Dakota Northern Mariana Islands Oregon South Dakota Utah Washington Wyoming

Article Information

General Information

Article ID
A58798

Article Title
Response to Comments: Glucose Monitors – DL33822

Article Type
Response to Comments

Original Effective Date
06/03/2021

Retirement Date
N/A

AMA CPT / ADA CDT / AHA NUBC Copyright Statement

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

Copyright © 2023, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the American Hospital Association (AHA) copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB‐04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312‐893‐6816.

Making copies or utilizing the content of the UB‐04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB‐04 Manual and/or codes and descriptions; and/or making any commercial use of UB‐04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. The American Hospital Association (the "AHA") has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliates.

Article Guidance

Article Text

During the 45-day comment period, which was open from 12/17/2020 through 01/30/2021, the DME MACs received a total of 26 comments* from 47 commenters.

*This count refers to the total comments/submissions received on this proposed local coverage determination as of January 30, 2021. Note: The MACs review all submitted comments; however, MACs may choose to consolidate similar thematic comments, redact or withhold certain submissions (or portions thereof) such as those containing private or proprietary information, inappropriate language or duplicate/near duplicate submissions from a mass-mailing campaign. This can result in discrepancies between this count and the number of responses to comments.

Introduction to Responses

The DME MACs appreciate the comments received from stakeholders during the open comment period on the proposed Glucose Monitors Local Coverage Determination (LCD).

Pursuant to the CMS Program Integrity Manual (CMS Pub. 100-08) Chapter 13:

In conducting a review, MACs shall use the available evidence of general acceptance by the medical community, such as published original research in peer-reviewed medical journals, systematic reviews and meta-analyses, evidence-based consensus statements and clinical guidelines.

Accordingly, the final policy and our response to comments are based on the best currently available published clinical evidence, to support: (1) removal of the coverage criteria requiring beneficiary use of a blood glucose monitor (BGM) and performing frequent (four or more times a day) testing in order to qualify for a continuous glucose monitor (CGM); and, (2) a change in CGM coverage criteria to allow qualification of individuals using multiple daily administrations of any insulin (including inhaled insulin, Afrezza).

Response To Comments

Number	Comment	Response
1	Many commenters indicated their support for removal of the coverage criteria requiring beneficiary use of a BGM and performing frequent (four or more times a day) testing in order to qualify for a CGM.	The DME MAC Medical Directors would like to thank the beneficiaries, suppliers, physicians, manufacturers, associations, and others for taking the time to submit detailed comments and support for the proposed changes to the Glucose Monitors LCD. The policy will be finalized as proposed with the removal of the requirement for frequent testing of ≥4 times per day on a BGM to qualify for a CGM.
2	Many commenters indicated their support for the change in CGM coverage criteria to allow qualification of individuals using multiple daily administrations of any insulin (including inhaled insulin, Afrezza).	The DME MAC Medical Directors would like to thank the beneficiaries, suppliers, physicians, manufacturers, associations, and others for taking the time to submit detailed comments and support for the proposed changes to the Glucose Monitors LCD. The policy will be finalized as proposed and allow for multiple daily administrations of any insulin in order to qualify for CGM.
3	One commenter requested Medicare coverage of Afrezza.	Coverage and reimbursement of Afrezza is not under the jurisdiction of the DME MACs, but may be available through other parts of the Medicare program. The proposed change to the DME MAC LCD is to allow the use of Afrezza as an alternative to injected insulin as a pathway to coverage of a CGM device.
4	Several commenters requested that inhaled insulin, Afrezza, be added to the CMS’s Part D Senior Savings Model.	This comment is outside the scope of the LCD reconsideration and should be directed to CMS. Additional information on CMS’s Part D Senior Savings Model is available at: https://innovation.cms.gov/innovation-models/part-d-savings-model.
5	Several commenters requested the removal of the CGM coverage criterion requiring the “beneficiary is insulin-treated with multiple (three or more) daily administrations of insulin or a Medicare-covered continuous subcutaneous insulin infusion (CSII) pump.”	The DME MAC Medical Directors thank the commenters for the feedback and are sensitive to these concerns; however, this comment is outside the scope of the current LCD reconsideration requests and the proposed changes to the LCD.
6	Several commenters indicated that excluding patients that use insulin <3 times per day from CGM coverage adds to the existing disparities in medicine and affects minorities and those with fewer resources disproportionately.	The DME MAC Medical Directors thank the commenters for the feedback and we share your concerns related to how medical policies can disproportionately affect minorities and those with fewer resources. However, this comment is outside the scope of the current LCD reconsideration requests and the proposed changes to the LCD.
7	Several commenters requested the removal of the CGM coverage criterion requiring “frequent adjustment by the beneficiary on the basis of BGM or CGM testing results.”	The DME MAC Medical Directors thank the commenters for the feedback. This criterion is intended to ensure that beneficiaries are using CGM readings to actively guide their diabetes therapy. It is not a mandate that insulin dose adjustments must be made if glucose levels are within the target range as established collaboratively with their treating practitioner. The Policy Specific Documentation Requirements section in the LCD-related policy article has been updated to clarify the intent of this criterion.
8	Several commenters suggested removing the words “Medicare-covered” from the coverage criterion that requires “the beneficiary is insulin-treated with multiple (three or more) daily administrations of insulin or a Medicare-covered continuous subcutaneous insulin infusion (CSII) pump” to allow coverage for beneficiaries using disposable pumps not covered under the DME MAC policy.	The DME MAC Medical Directors agree and the LCD will be finalized with the following language: “The beneficiary is insulin-treated with multiple (three or more) daily administrations of insulin or a continuous subcutaneous insulin infusion (CSII) pump; and,”
9	Several commenters suggested modifying the coverage criteria to allow telehealth visits to meet the requirements for the initial and follow-up in-person visits.	This comment is outside the scope of the current LCD reconsideration requests and the proposed changes to the LCD.
10	One commenter suggested modifying the coverage criteria for beneficiaries entering Medicare to only require a “New to Medicare” welcome visit and not require recertification once Medicare eligible.	This comment is outside the scope of the current LCD reconsideration requests and the proposed changes to the LCD. Documentation requirements for equipment retained from another payer are available in the Standard Documentation Requirements for All Claims Submitted to DME MACs Policy Article (A55426). The policy article includes the following (in relevant part and emphasis added): “When a beneficiary receiving a DMEPOS item from another payer (including a Medicare Advantage plan) becomes eligible for the Medicare Fee For Service (FFS) program, the first Medicare claim for that item or service is considered a new initial Medicare claim. Medicare does not automatically continue coverage for any item obtained from another payer when a beneficiary transitions to Medicare coverage. For Medicare to provide payment, the beneficiary must meet all Medicare coverage, coding, and documentation requirements for the DMEPOS items in effect on the DOS of the initial Medicare claim.”
11	Several commenters suggested modifying the coverage criteria to allow a yearly face to face visit to assess adherence instead of every 6 months.	This comment is outside the scope of the current LCD reconsideration requests and the proposed changes to the LCD.
12	One commenter requested the External Infusion Pumps (L33794) and Glucose Monitors (L33822) policies be aligned to require reassessment visits at the same time intervals for CGM and insulin infusion pumps.	This comment is outside the scope of the current LCD reconsideration requests and the proposed changes to the LCD.
13	One commenter indicated the DME MACs should not require monthly reassessment of CGM usage.	This comment is outside the scope of the current LCD reconsideration requests and the proposed changes to the LCD.
14	One commenter indicated that use of other sulfonylureas should qualify a beneficiary for CGM.	This comment is outside the scope of the current LCD reconsideration requests and the proposed changes to the LCD.
15	Several commenters requested coverage of CGM for individuals with chronic kidney disease without diabetes mellitus.	This comment is outside the scope of the current LCD reconsideration requests and the proposed changes to the LCD. National Coverage Determination (NCD) 40.2 limits coverage of home blood glucose monitors to beneficiaries with diabetes. Additional information on the NCD reconsideration process is available here: https://www.cms.gov/Medicare/Coverage/DeterminationProcess
16	One commenter, with the support of many other clinicians and beneficiaries via a signed petition, requested coverage of CGM for hypoglycemic beneficiaries without diabetes.	This comment is outside the scope of the current LCD reconsideration requests and the proposed changes to the LCD. National Coverage Determination (NCD) 40.2 limits coverage of home blood glucose monitors to beneficiaries with diabetes. Additional information on the NCD reconsideration process is available here: https://www.cms.gov/Medicare/Coverage/DeterminationProcess
17	One commenter requested coverage of CGM for individuals with physical disabilities preventing them from testing 4x/day with a BGM.	The DME MAC Medical Directors thank the commenter for the feedback and we share your concerns that beneficiaries with physical disabilities may not be able to use a standard blood glucose monitor. The requirement that a beneficiary has been using a BGM and performing frequent (four or more times a day) testing of their blood sugar has been removed from the current LCD, as reflected in the criteria for a CGM device in the proposed LCD.
18	Several commenters submitted their own proposed coverage criteria for consideration.	The DME MAC Medical Directors appreciate the comments and suggestions for additional changes to the CGM criteria; however, requests for changes to criteria beyond what was proposed are outside the scope of the current requests and will require a new reconsideration.
19	One commenter indicated that the only coverage criterion for a CGM should be a diagnosis of diabetes mellitus.	This comment is outside the scope of the current LCD reconsideration requests and the proposed changes to the LCD.
20	One commenter provided a general comment on the need for broader approval of CGMs to help get the hyperglycemia epidemic under control.	The finalized changes to the LCD are relaxing the coverage criteria for CGMs and will therefore allow for broader approval of CGMs.
21	One commenter requested that the policy provide guidance on beneficiaries needing to return to BGM after unsuccessful CGM use.	This comment is outside the scope of the current LCD reconsideration requests and the proposed changes to the LCD.
22	Several commenters requested the simplification of CGM documentation requirements and suggested consultation with the supplier community on the proposed changes.	This comment is outside the scope of the current LCD reconsideration requests and the proposed changes to the LCD.
23	Several commenters submitted questions or comments regarding the CMS proposed rule CMS-1738-P and requested the policy be updated with this revision to incorporate the proposed changes.	This comment is outside the scope of the current LCD reconsideration requests and the proposed changes to the LCD. The DME MACs are not able to make any policy changes based on proposed rules.
24	One commenter indicated that the DME MACs should not require glucose logs be submitted every 30 days.	This comment is outside the scope of the current LCD reconsideration requests and the proposed changes to the LCD. Additionally, the current LCD does not require monthly submission of glucose logs.
25	One commenter requested a pathway to coverage for all 3 components of an interoperable closed-loop system (the CGM, insulin pump, and software).	This comment is outside the scope of the current LCD reconsideration requests and the proposed changes to the LCD.
26	One commenter requested a technical correction in the Summary of Evidence background section to the frequency range in which CGMs measure interstitial fluid glucose levels.	The suggested change was reviewed and is reflected in the final LCD. This minor technical change does not affect the level of evidence evaluation or the conclusion.

Coding Information

CPT/HCPCS Codes

Expand All | Collapse All

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

ICD-10-CM Codes that Support Medical Necessity

Expand All | Collapse All

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

ICD-10-CM Codes that DO NOT Support Medical Necessity

Expand All | Collapse All

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

ICD-10-PCS Codes

Expand All | Collapse All

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

Additional ICD-10 Information

Bill Type Codes

Code	Description

Revenue Codes

Code	Description

Coding Table Information

Excluded CPT/HCPCS Codes - Table Format

Code	Descriptor Generic Name	Descriptor Brand Name	Exclusion Effective Date	Exclusion End Date	Reason for Exclusion
			N/A	N/A

Non-Excluded CPT/HCPCS Ended Codes - Table Format

Code	Descriptor Generic Name	Descriptor Brand Name	Exclusion Effective Date	Exclusion End Date	Reason for Exclusion

Revision History Information

N/A

Associated Documents

Updated On	Effective Dates	Status
05/26/2021	06/03/2021 - N/A	Currently in Effect	You are here

Keywords

N/A

Read the Article Disclaimer

Please review and accept the agreements in order to view Medicare Coverage documents, which may include licensed information and codes.

LICENSE FOR USE OF PHYSICIANS' CURRENT PROCEDURAL TERMINOLOGY, FOURTH EDITION ("CPT")

End User Point and Click Amendment:

CPT codes, descriptions and other data only are copyright 2023 American Medical Association. All Rights Reserved (or such other date of publication of CPT). CPT is a trademark of the American Medical Association (AMA).

You, your employees and agents are authorized to use CPT only as agreed upon with the AMA internally within your organization within the United States for the sole use by yourself, employees and agents. Use is limited to use in Medicare, Medicaid or other programs administered by the Centers for Medicare and Medicaid Services (CMS). You agree to take all necessary steps to insure that your employees and agents abide by the terms of this agreement.

Any use not authorized herein is prohibited, including by way of illustration and not by way of limitation, making copies of CPT for resale and/or license, transferring copies of CPT to any party not bound by this agreement, creating any modified or derivative work of CPT, or making any commercial use of CPT. License to use CPT for any use not authorized herein must be obtained through the AMA, CPT Intellectual Property Services, AMA Plaza 330 N. Wabash Ave., Suite 39300, Chicago, IL 60611-5885. Applications are available at the AMA Web site, http://www.ama-assn.org/go/cpt.

Applicable FARS\DFARS Restrictions Apply to Government Use.

AMA Disclaimer of Warranties and Liabilities.

CPT is provided "as is" without warranty of any kind, either expressed or implied, including but not limited to, the implied warranties of merchantability and fitness for a particular purpose. No fee schedules, basic unit, relative values or related listings are included in CPT. The AMA does not directly or indirectly practice medicine or dispense medical services. The responsibility for the content of this file/product is with CMS and no endorsement by the AMA is intended or implied. The AMA disclaims responsibility for any consequences or liability attributable to or related to any use, non-use, or interpretation of information contained or not contained in this file/product. This Agreement will terminate upon notice if you violate its terms. The AMA is a third party beneficiary to this Agreement.

CMS Disclaimer

The scope of this license is determined by the AMA, the copyright holder. Any questions pertaining to the license or use of the CPT should be addressed to the AMA. End Users do not act for or on behalf of the CMS. CMS DISCLAIMS RESPONSIBILITY FOR ANY LIABILITY ATTRIBUTABLE TO END USER USE OF THE CPT. CMS WILL NOT BE LIABLE FOR ANY CLAIMS ATTRIBUTABLE TO ANY ERRORS, OMISSIONS, OR OTHER INACCURACIES IN THE INFORMATION OR MATERIAL CONTAINED ON THIS PAGE. In no event shall CMS be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information or material.

Should the foregoing terms and conditions be acceptable to you, please indicate your agreement and acceptance by clicking below on the button labeled "I Accept".

LICENSE FOR USE OF CURRENT DENTAL TERMINOLOGY (CDT^TM)

The license granted herein is expressly conditioned upon your acceptance of all terms and conditions contained in this agreement. By clicking below on the button labeled "I accept", you hereby acknowledge that you have read, understood and agreed to all terms and conditions set forth in this agreement.

If you do not agree with all terms and conditions set forth herein, click below on the button labeled "I do not accept" and exit from this computer screen.

If you are acting on behalf of an organization, you represent that you are authorized to act on behalf of such organization and that your acceptance of the terms of this agreement creates a legally enforceable obligation of the organization. As used herein, "you" and "your" refer to you and any organization on behalf of which you are acting.

Subject to the terms and conditions contained in this Agreement, you, your employees and agents are authorized to use CDT only as contained in the following authorized materials and solely for internal use by yourself, employees and agents within your organization within the United States and its territories. Use of CDT is limited to use in programs administered by Centers for Medicare & Medicaid Services (CMS). You agree to take all necessary steps to ensure that your employees and agents abide by the terms of this agreement. You acknowledge that the ADA holds all copyright, trademark and other rights in CDT. You shall not remove, alter, or obscure any ADA copyright notices or other proprietary rights notices included in the materials.
Any use not authorized herein is prohibited, including by way of illustration and not by way of limitation, making copies of CDT for resale and/or license, transferring copies of CDT to any party not bound by this agreement, creating any modified or derivative work of CDT, or making any commercial use of CDT. License to use CDT for any use not authorized herein must be obtained through the American Dental Association, 211 East Chicago Avenue, Chicago, IL 60611. Applications are available at the American Dental Association web site, http://www.ADA.org.
Applicable Federal Acquisition Regulation Clauses (FARS)/Department of Defense Federal Acquisition Regulation supplement (DFARS) Restrictions Apply to Government Use. U.S. Government Rights Provisions.
Organizations who contract with CMS acknowledge that they may have a commercial CDT license with the ADA, and that use of CDT codes as permitted herein for the administration of CMS programs does not extend to any other programs or services the organization may administer and royalties dues for the use of the CDT codes are governed by their commercial license.
ADA DISCLAIMER OF WARRANTIES AND LIABILITIES. CDT is provided "as is" without warranty of any kind, either expressed or implied, including but not limited to, the implied warranties of merchantability and fitness for a particular purpose. No fee schedules, basic unit, relative values or related listings are included in CDT. The ADA does not directly or indirectly practice medicine or dispense dental services. The sole responsibility for software, including any CDT and other content contained therein, is with CMS; and no endorsement by the ADA is intended or implied. The ADA expressly disclaims responsibility for any consequences or liability attributable to or related to any use, non-use, or interpretation of information contained or not contained in this file/product. This Agreement will terminate upon notice to you if you violate the terms of this Agreement.

The ADA is a third party beneficiary to this Agreement.
CMS DISCLAIMER. The scope of this license is determined by the ADA, the copyright holder. Any questions pertaining to the license or use of the CDT should be addressed to the ADA. End Users do not act for or on behalf of the CMS. CMS disclaims responsibility for any liability attributable to end user use of the CDT. CMS will not be liable for any claims attributable to any errors, omissions, or other inaccuracies in the information or material covered by this license. In no event shall CMS be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information or material.

The license granted herein is expressly conditioned upon your acceptance of all terms and conditions contained in this agreement. If the foregoing terms and conditions are acceptable to you, please indicate your agreement by clicking below on the button labeled "I Accept". If you do not agree to the terms and conditions, you may not access or use software. Instead you must click below on the button labeled "I Do Not Accept" and exit from this computer screen.

License For Use of National Uniform Billing Committee (NUBC) UB-04

These materials contain NUBC Official UB-04 Specifications (UB-04 Data), which is copyrighted by the American Hospital Association (AHA).

THE LICENSE GRANTED HEREIN IS EXPRESSLY CONDITIONED UPON YOUR ACCEPTANCE OF ALL TERMS AND CONDITIONS CONTAINED IN THIS AGREEMENT. BY CLICKING BELOW ON THE BUTTON LABELED "I ACCEPT", YOU HEREBY ACKNOWLEDGE THAT YOU HAVE READ, UNDERSTOOD AND AGREED TO ALL TERMS AND CONDITIONS SET FORTH IN THIS AGREEMENT.

IF YOU DO NOT AGREE WITH ALL TERMS AND CONDITIONS SET FORTH HEREIN, CLICK BELOW ON THE BUTTON LABELED "I DO NOT ACCEPT" AND EXIT FROM THIS COMPUTER SCREEN. IF YOU ARE ACTING ON BEHALF OF AN ORGANIZATION, YOU REPRESENT THAT YOU ARE AUTHORIZED TO ACT ON BEHALF OF SUCH ORGANIZATION AND THAT YOUR ACCEPTANCE OF THE TERMS OF THIS AGREEMENT CREATES A LEGALLY ENFORCEABLE OBLIGATION OF THE ORGANIZATION. AS USED HEREIN, "YOU" AND "YOUR" REFER TO YOU AND ANY ORGANIZATION ON BEHALF OF WHICH YOU ARE ACTING.

Subject to the terms and conditions contained in this Agreement, you, your employees, and agents are authorized to use UB-04 Data only as contained in the following authorized materials and solely for internal use by yourself, employees and agents within your organization within the United States and its territories. Use of UB-04 Data is limited to use in programs administered by Centers for Medicare & Medicaid Services (CMS). You agree to take all necessary steps to ensure that your employees and agents abide by the terms of this Agreement. You acknowledge that the AHA holds all copyright, trademark, and other rights in UB-04 Data. You shall not remove, alter, or obscure any AHA copyright notices or other proprietary rights notices included in the materials.
Any use not authorized herein is prohibited, including, by way of illustration and not by way of limitation, making copies of UB-04 Data for resale and/or license, transferring copies of UB-04 Data to any party not bound by this agreement, creating any modified or derivative work of UB-04 Data, or making any commercial use of UB-04 Data. License to use UB-04 Data for any use not authorized herein must be obtained through the American Hospital Association, 155 N. Wacker Drive, Suite 400, Chicago, Illinois, 60606. Applications are available at the NUBC website, http://www.nubc.org/.
The UB-04 Data included in this product is commercial technical data and/or computer databases and/or commercial computer software and/or commercial computer software documentation, as applicable, which was developed exclusively at private expense by the American Hospital Association, 155 N. Wacker Drive, Suite 400, Chicago, Illinois 60606. U.S. Government rights to use, modify, reproduce, release, perform, display, or disclose these technical data and/or computer data bases and/or computer software and/or computer software documentation are subject to the limited rights restrictions of DFARS 252.227-7015(b)(2) (November 1995) and/or subject to the restrictions of DFARS 227.7202-1(a) (June 1995) and DFARS 227.7202-3(a) (June 1995), as applicable for U.S. Department of Defense procurements and the limited rights restrictions of FAR 52.227-14 (December 2007) and FAR 52.227-19 (December 2007), as applicable, and any applicable agency FAR Supplements, for non-Department of Defense Federal procurements.
AHA DISCLAIMER OF WARRANTIES AND LIABILITIES. UB-04 Data is provided "as is" without warranty of any kind, either expressed or implied, including but not limited to, the implied warranties of merchantability and fitness for a particular purpose. The sole responsibility for the software, including any UB-04 Data and other content contained therein, is with the Medicare/Medicaid Contractor or the CMS; and no endorsement by the AHA is intended or implied. The AHA expressly disclaims responsibility for any consequences or liability attributable to or related to any use, non-use, or interpretation of information contained or not contained in this file/product. This Agreement will terminate upon notice to you if you violate the terms of this Agreement. The AHA is a third-party beneficiary to this Agreement.
CMS DISCLAIMER. The scope of this license is determined by the AHA, the copyright holder. Any questions pertaining to the license or use of the UB-04 Data should be addressed to the AHA. End users do not act for or on behalf of the CMS. CMS DISCLAIMS RESPONSIBILITY FOR ANY LIABILITY ATTRIBUTABLE TO END USER USE OF THE UB-04 DATA. CMS WILL NOT BE LIABLE FOR ANY CLAIMS ATTRIBUTABLE TO ANY ERRORS, OMISSIONS, OR OTHER INACCURACIES IN THE INFORMATION OR MATERIAL COVERED BY THIS LICENSE. In no event shall CMS be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information or material.

Submit Feedback/Ask a Question

Response to Comments: Glucose Monitors – DL33822

Document Note

Note History

Contractor Information

Article Information

General Information

CMS National Coverage Policy

Article Guidance

Response To Comments

Coding Information

Bill Type Codes

Revenue Codes

CPT/HCPCS Codes

Group 1

CPT/HCPCS Modifiers

Group 1

ICD-10-CM Codes that Support Medical Necessity

Group 1

ICD-10-CM Codes that DO NOT Support Medical Necessity

Group 1

ICD-10-PCS Codes

Group 1

Additional ICD-10 Information

Bill Type Codes

Revenue Codes

Other Coding Information

Group 1

Coding Table Information

Revision History Information

Associated Documents

Keywords

Page Help for Article - Response to Comments: Glucose Monitors – DL33822 (A58798)

Introduction

Finding a specific code

More information

Printing a Document to PDF

Get email updates

CMS & HHS WEBSITES

HELPFUL LINKS

RSS FEEDS